SCHEMBL1375448

SCHEMBL1375448

Fc1cccc(Cl)c1N1CC[N]CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
MPI P34949 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NOTUM Q6P988 1/20 0.35
HTR1A P08908 1/20 0.35
SLC6A2 P23975 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
PDE7A Q13946 2/20 0.34
KCNH2 Q12809 1/20 0.34
GFER P55789 1/20 0.34
C5AR1 P21730 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7286192 0.87 NOTUM (0.43) GAAKDM4EALDH1A1L3MBTL1NOTUM
SCHEMBL23064539 0.83 ALDH1A1 (0.48) CYP2A13GAAMAPTKMT2AKDM4E
SCHEMBL21447982 0.79 DRD2 (0.54) ALDH1A1HTR1A
SCHEMBL17543221 0.77 PDE7A (0.38) CYP2A13MAPTKMT2AKDM4EMEN1
SCHEMBL30241928 0.77 ALDH1A1 (0.40) CYP2A13GAAMAPTKMT2AKDM4E
SCHEMBL17542732 0.77 SMN1; SMN2 (0.40) CYP2A13KMT2AKDM4EMEN1ALDH1A1
SCHEMBL30079590 0.76 HTR3E (0.47) KMT2AMEN1NOTUMKCNH2C5AR1
SCHEMBL14804201 0.72 KDM4E (0.57) CYP2A13GAAKDM4EALDH1A1L3MBTL1
SCHEMBL17543826 0.72 LMNA (0.48) CYP2A13GAAMAPTKDM4EALDH1A1
SCHEMBL918064 0.71 CYP2A13 (0.68) CYP2A13KMT2AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed
EP-2346821-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS Exelixis, Inc. (US) 2011-07-27 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 CYP2A13 4815/4885GAA 4401/4885MAPT 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.